Citius Pharmaceuticals (CTXR) Tax Provisions (2022 - 2026)

Citius Pharmaceuticals (CTXR) has reported Tax Provisions for 5 consecutive years, with -$107347.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions fell 140.62% year-over-year to -$107347.0; the trailing twelve-month figure through Jun 2026 stood at $189923.0 (down 79.72% YoY), and the FY2025 full-year result was $1.1 million, up 83.5% from the prior year.
• Tax Provisions grew to -$107347.0 in Q2 2026 per CTXR's latest filing, from -$231210.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $264240.0 in Q4 2024 and bottomed at -$231210.0 in Q1 2026.
• Historically, Tax Provisions has averaged $142309.5 across 5 years, with a median of $144000.0 in 2022.
• The sharpest annual moves came in 2024 and 2026: Tax Provisions soared 83.5% in 2024, then tumbled 187.5% in 2026.
• Over 5 years, Tax Provisions stood at $144000.0 in 2022, then changed by 0.0% to $144000.0 in 2023, then jumped by 83.5% to $264240.0 in 2024, then changed by 0.0% to $264240.0 in 2025, then plunged by 140.62% to -$107347.0 in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered -$107347.0, -$231210.0, and $264240.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.